The acceptability to patients with macular disease to have retreatment decisions being made by artificial intelligence

黄斑病患者对由人工智能做出再次治疗决定的接受程度

阅读:2

Abstract

INTRODUCTION: Artificial Intelligence (AI) refers to a system that can take input data and subsequently provide a prediction-based output. In some instances, these systems can provide a recommendation for a clinical decision. Such systems are being developed to analyse retinal images and to determine if there is active retinal disease with a view to directly influencing treatment decisions. This study looks at whether AI-based decision making is acceptable to patients with macular disease. METHODS: The Macular Society has a monthly newsletter which it sends out to its members and subscribers in which views were canvassed. They were offered participation in a conjoint analysis exploring human or AI decision making, the error rate, the time to follow up and whether the scans were double read by a human or AI tool. Options were presented in a random order and participants were asked to rank the suitability of different scenarios in order of preference. RESULTS: The task was completed by 181 participants. The two most important factors were the error rate (p < 0.0001) and whether the results were being checked (p < 0.0001). Participants did not state a preference for the first and/or second reader being either human or AI and there was a non-significant trend for rapid turnaround. CONCLUSIONS: Patients with macular disease find AI to be acceptable in the assessment of retinal images. The most important factors to patients relate to the accuracy of the decision making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。